Wellness focus: Glutathione supports antioxidant activity, detoxification, and cellular health
present in ~40% of PV patients Plethora (facial redness/ruddy complexion) due to increased RBC mass and skin hyperemia Headache, dizziness, and visual disturbances from hyperviscosity and reduced cerebral blood flow Splenomegaly palpable in 7090% of PV patients from extramedullary hematopoiesis Thrombotic events (DVT, stroke, MI, Budd-Chiari syndrome) major complications from hyperviscosity Erythromelalgia burning pain/redness of hands and feet due to platelet-mediated microvascular occlusion Gout from elevated uric acid due to increased cell turnover Hypertension common comorbidity in PV Bleeding tendency paradoxically, despite elevated platelets, qualitative platelet dysfunction can cause GI bleeding Signs and symptoms that are routinely associated with a confirmed diagnosis of anemia or polycythemia (e.g., tachycardia, fatigue, pallor with anemia
Use case alignment Certain applications favor oral delivery
The peroxisome-proliferator activated receptor-gamma agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus
Morning dosing allows peptide activity during daytime recovery and potential training sessions
PureRawz said the compounds highlighted in the overview reflect several research themes heading into 2026, including multi-receptor agonism in metabolic research, selective secretagogue design in endocrine pharmacology, peptide-mediated tissue-regeneration modeling, synthetic peptide analog design, receptor-selectivity analysis, and laboratory evaluation of peptide stability
